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The World Health Organization (WHO) is the special-
ized agency of the UN on public health. It gives world-
wide guidance in the field of health, sets global standards
for health, cooperates with governments to strengthen na-
tional health care programs, and develops and transfers
appropriate health technology, information, and stan-
dards. Within the WHO European region, health status
and health expenditures vary greatly. In this paper, dis-
parities between health status, health services, and health
care expenditures between countries of the WHO Euro-
pean region are presented. The objectives, performance,
and dilemmas facing health care systems are discussed,
including the recent performance ranking published by
the WHO. The paper focuses particularly on access to
medicines, their appropriate use, and rising drug expen-
ditures. Strategies used by European countries to im-
prove drug use and contain health care expenditures are
outlined. Finally, the future of pharmaceuticals and pub-
lic health is explored.
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Introduction
 
Founded in 1948, the World Health Organization
(WHO) is a United Nations (UN) specialized agency
that promotes technical cooperation in health care
among nations, carries out programs to eradicate
and eliminate disease, and strives to improve health-
related quality of life. Its objective is the achieve-
ment by all people of the highest possible level of
health. In support of its objective, the organization
has four main functions: providing worldwide
guidance in the field of health care, setting global
health standards, cooperating with governments to
strengthen national health care programs, and de-
veloping and transferring appropriate health care
technology, information, and standards. The Euro-
pean region of the WHO stretches from Iceland to
the Bering Strait and from Norway to Israel, com-
prising 51 member states, including the whole
former Soviet Union. There are large variations
across this region in health status and health care
systems. This paper reports the WHO perspective
on the goals, performance, and dilemmas of health
care systems in the European region and explores
future directions in pharmaceutical policy and cost
containment strategies.
 
Health Status and Health Expenditures
 
Indicators of health such as life expectancy and in-
fant mortality reflect wide variations in health sta-
tus across the countries of the WHO European
Region [1]. Although life expectancy has been in-
creasing steadily in Western European countries
since the 1970s, a drastic decline was observed in
the countries of the former Soviet Union from the
early 1990s due to the collapse of the health care
system and social disruption. Now life expectancy
and health status in these newly independent states
is slowly improving. Similarly, infant mortality rates
in the Central Asian Republics are still well higher
than in Eastern European countries.
The economics of European health care systems
also reflects wide disparity. The percentage of gross
domestic product (GDP) spent on health care in Eu-
ropean countries varies between more than 10% to
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less than 3% (Fig. 1). While several Western Euro-
pean countries use about 10% of their GDP on
health care, this figure is lower than 4% in most
countries of the former Soviet Union. Great varia-
tions are also observed in drug expenditures (Ta-
ble 1). Most Western European countries spend
between US$200 and US$350 per capita on medi-
cines while most countries of the former Soviet
Union spend far less than US$100 per capita on
medications. At the bottom of the scale, some
Eastern European countries and certain Central
Asian Republics have per capita drug expenditures
of less than US$10.
There are also great disparities in the percent-
age of health care expenditures spent on medicines
among countries worldwide (Fig. 2). Poorer coun-
tries spend a greater percentage of health care ex-
penditures on medicines (up to 66% in some de-
veloping countries) in marked contrast with figures
observed in affluent, developed countries (7–20%).
In many poor Eastern European countries, cover-
age by social insurance or by a tax-based system is
still limited, and a substantial part of the drug ex-
penditure is in the form of out-of-pocket payment.
In a number of poor countries, drug expenditures
are the second largest household expenditure; this
reflects the tremendous importance of the role of
medicines in health care.
A growing concern from the perspective of poli-
cymakers is the rise in drug expenditures. In 1980,
most Organization for Economic Cooperation and
Development (OECD) countries were spending be-
tween 0.5 and 1% of their GDP on medicine; in
1996 several were spending more than 1.5% of
their GDP on drugs and in some countries more
than 2% (Fig. 3). Drug expenditures continue to
rise, and in 1999 drug expenditure increases ranged
from 5% to 15% for a number of OECD countries
[3]. The biggest increase was observed in the United
States, at 18% (Fig. 4). Relationships between in-
creased drug spending, shifts in health care costs,
and improved health are often difficult to analyze.
 
Health Care Systems: Goals, Performance, 
and Dilemmas
 
Health Care System Goals
 
Two years ago, the ministers of health of the Eu-
ropean region adopted the Health 21 Policy Frame-
work, outlining health policy for European coun-
tries for the 21st century. Their goal was to achieve
good health for the entire population, at the same
time reducing disease incidence.
There are four core values serving as a base for
health care systems:
• Human rights: Every citizen in European mem-
ber states has a right to health;
• Equity: Individuals in European countries should
have equal access to health and health care ser-
vices;
• Solidarity: There is a responsibility of society
as a whole for everyone to contribute to main-
taining, protecting, and achieving health; and
• Participation and accountability: Health is not
solely the responsibility of physicians or gov-
ernments, but of a variety of sectors. Health
status is also a reflection of social policy, edu-
cation and environment.
Member states recognize the need to be much
more outcome oriented and know what type of in-
vestments contribute the most to health. There is
also an increasing need to examine integrated care,
evaluating systems as a whole rather than as seg-
ments. Finally, there is a need for participation
from everyone in society including government, in-
dustry, patients, and health care providers.
Figure 1 Total health expenditure as a percentage of gross
domestic product in Europe, 1995 or latest available year.
EU, European Union; NORDIC, Scandinavian countries;
CCEE, Central and Eastern European countries; CAR, Cen-
tral Asian republics; NIS, Newly independent states.
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Performance
 
In its 2000 Annual Report, the WHO examined
performance of health care systems. Three areas
were identified and for each a set of performance
indicators was defined:
• Health: health status of people, including life
expectancy and infant mortality.
• Responsiveness: how responsive the health
care system is to the needs of society and to the
needs of patients, including quality of services.
A difficult and controversial area, based on
available data, a set of indicators was determined
to allow the WHO to compare how countries
respond to the health care needs in popula-
tions.
• Fairness in financing: the issues of equity and
solidarity. Health is a human right and the
whole population should have equitable access
to good health care.
A methodology was developed over a period of a
year and a half to examine the performance of
health care systems and relate the achievement of
these indicators to investment in the health care sec-
tor (the efficiency factor). A ranking of countries
based on the performance of their health care sys-
 
Table 1
 
Expenditures per capita on medicines in WHO European region, 1996–1997
 
Expenditure
per capita (USD) Western Europe Eastern Europe Newly independent states
Total regional
population
(millions)
 

 
$300 Austria, Belgium, France,
Germany, Iceland,
Switzerland
164
$200–$300 Denmark, Finland, Italy,
Luxembourg, Netherlands,
Norway, Portugal, Sweden,
Great Britain
163
$100–$200 Greece, Ireland, Spain Czech Republic,
Hungary, Slovenia
76
$20–$100 Croatia, Estonia, Latvia,
Lithuania, Macedonia,
Poland, Slovakia
Russia 206
$10–$20 Romania Armenia, Bulgaria,
Georgia, Kazakstan,
Ukraine
109
 

 
$10 Albania Azerbaijan, Kyrgyzstan,
Moldova, Tajikistan, 
Turkmenistan, Uzbekistan
54
Figure 2 Pharmaceutical spending as a percentage of total health spending.
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tem was produced and published in the 2000 WHO
Annual Report [2]. Almost all Western European
countries ranked among the 25 top countries in
the world, but variations were identified. France
was considered to have the best performing health
care system (Fig. 5). This report has triggered a lot
of debate; its objective was not to provide an-
swers, but rather to initiate a discussion on how
countries could better measure the results achieved
in their health sector and be more creative in eval-
uating the performance of their health care system
and in setting goals and standards. In recent dis-
cussions it was agreed that WHO, together with
all member states, will continue to work toward
improvement in this complex field.
Key policy transitions were one important issue
in assessing performance of health care systems. As
countries strive to create more outcome-oriented,
better performing and more efficient health care sys-
tems, the role of government is to provide strategic
stewardship (in the form of guidance and leader-
ship) to the health care sector. Many health systems
tend to pool their resources in order to increase ef-
fectiveness and increase their negotiating power. In
many systems there is a split between providers and
purchasers of services, and increasingly health care
systems are focusing explicitly on quality develop-
ment and cost-effectiveness considerations.
 
Access to Medicines
 
In the realm of pharmaceutical policy, four sets of
goals have been set forward by the WHO [4].
• Equitable access to needed drugs of proven
quality and safety for the whole population;
• Improvement of drug use, which is closely re-
lated to outcomes;
• Ensuring value for money, making sure that in a
context of constrained resources optimal value
is obtained for the money spent; and
• Ensuring that national drug policies build pub-
lic and professional confidence.
In the eastern part of the European region, de-
velopment of pharmaceutical policies is focusing
on access to essential drugs [5]; between 20% and
50% of the population in several newly indepen-
dent states still does not have access to essential
drugs. Four components are considered for devel-
oping access to medicines:
• Rational selection of appropriate and needed
drugs;
• Affordable prices for those drugs;
• Sustainable financing, either by taxes, co-pay-
ments, or a combination of these; and
• A reliable drugs supply system, not yet avail-
able in many countries.
Figure 3 Drug expenditures in OECD countries as a per-
centage of GDP.
Figure 4 Percentage rise in drug expenditures in 1999 in
OECD countries.
I, Italy; S, Sweden; E, Spain; D, Germany; Su, Finland.
Figure 5 Ranking of countries based on the performance of
their health care system as evaluated by the World Health
Organization.
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Rising Drug Expenditures
 
Currently, every country is facing the dilemma of ris-
ing drug expenditures and limited drug budgets.
Health care systems are subjected to the growing de-
mands of consumers and patients, pressures from
doctors and pharmacists, and pressure from the phar-
maceutical industry. At the same time, irrational and
unnecessary drug prescribing practices are still taking
place throughout European countries. Uncertainties
regarding usefulness of medicines and treatment out-
comes are common. Tremendous variations in clini-
cal practice between European countries are observed
which are not clearly linked to differences in health
status. Underuse of new, effective treatments is of
concern, while ineffective treatments continue to be
used in many countries.
Numerous factors are causing a rise in drug ex-
penditure. A variety of studies performed in different
countries over the past few years point to higher vol-
umes of drugs and higher prices, also resulting from
an increased disease burden due to an aging popula-
tion [6]. Concretely, this means that there is a shift
to newer and often more expensive medicines in the
same therapeutic class, although the extent of added
benefit is not always well established; many condi-
tions that were not managed many years ago are now
being treated prophylactically; new lifestyle drugs are
entering the market; new drugs are becoming avail-
able for diseases that were previously untreatable
(e.g., multiple sclerosis); new diseases (e.g., AIDS) are
provoking research and development of new drug
treatments, and finally, the shift to ambulatory care
from hospital care observed in many countries is hav-
ing serious implications for drug expenditure.
 
Improving Drug Use and Containing Cost
 
Strategies employed by European countries to achieve
the goals of accessibility, rational drug use, and added
value for money include educational and information
initiatives, managerial, administrative, and financial
measures. Among educational initiatives are develop-
ment of university programs, practice guidelines, pre-
scriber information, continuing education programs,
drug committees, feedback on prescription data,
patient information packages implemented through
Ministries of Health, health insurance institutions,
professional associations, etc. Managerial and ad-
ministrative measures to improve drug use and con-
tain costs include positive and negative lists, refer-
ence pricing systems and reimbursement schemes,
disease management strategies, practice guidelines
and restrictions on distribution and prescription to
certain parts of the health care system or certain
providers. Managerial measures also include regula-
tion of marketing and commercial information.
With respect to financial measures, several countries
are using fixed or directive budgets for prescribing
specifically to regions or hospitals. A variety of mea-
sures have been put in place, such as price regula-
tion, price/volume agreements, copayment schemes,
financial incentives to pharmacists to improve phar-
macy services, differential reimbursement rates, and
promotion of generic drugs. It is a rapidly changing
panorama with a number of measures switching in
rapid sequence from one to another.
The effect of increased drug costs on overall health
expenditures is hotly debated around the world. Price
control is a very controversial subject with differing
implications across Europe. Most high-income coun-
tries of Western Europe have price control systems
that have been shown to contain the individual prices
of drugs. However, their effect on total drug expendi-
ture remains unclear. A number of factors are in-
volved; low drug prices, high consumption, and high
overall expenditures are observed in France, while
high prices, low consumption, and relatively low ex-
penditures dominate in Denmark. High prices, high
consumption, and high expenditures are reported in
Germany. For the eastern part of the European re-
gion, price control has a different function. Because
many patients have to pay out of their own pocket,
keeping individual drug prices down is essential to
permit access to essential drugs, so prices should be
based on health need and ability to pay.
On a global level, discussion regarding drug costs
focuses on generic drugs, and in recent years has fo-
cused very much on access to HIV/AIDS drugs for
low-income countries. Although increase in the share
of generic drugs in European markets is relatively low
with the exception of a few countries, major savings
can be found when generic drugs are available. The
other key issue is the availability of drugs needed for
HIV/AIDS and treatment of tropical diseases in the
poorest countries that lack the resources to pay
global prices. These issues have to be tackled from
a worldwide perspective, seeking partnerships with
manufacturers, but also in the trade-offs in the drug
market as a whole. Again, in this area, access to these
drugs should be driven more by health needs than by
the ability of individual patients or health care sys-
tems to pay.
 
Challenges Ahead
 
Key Issues for the Future
 
The WHO has identified a number of strategic tar-
gets for future development. There is a continuous
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entry of new products onto the market and a gen-
eralized failure to link drug development to health
and health system needs. Although the pharmaceu-
tical industry operates from a global perspective,
health care systems operate from a national point
of view, and this may create tension among vary-
ing perspectives and interests. Diseases such as
tuberculosis, malaria, acute respiratory infections,
and others continue to kill 10 million people each
year. Over the last 30 years very few new, effective
drugs for tropical diseases have come onto the
market, while at the same time a number of life-
style drugs have entered it. How can we make real
innovation focused on worldwide health needs
possible under the prevailing conditions? Criticism
of “me too” drugs entering the market must be
balanced by the potential benefits of therapeutic
class competition, an area that requires further
analysis. From the national health policy and in-
dustry perspective it is desirable to have a strong,
innovative pharmaceutical industry as well as a
strong, efficient generic industry. However this dis-
cord in objectives among the various sectors gives
rise to considerable policy discussion.
With respect to the therapeutic value of new
drugs, it is well established that when a drug en-
ters the market, uncertainty regarding its effective-
ness persists; its place and its value in the real
world will be uncovered by medical practice. Sev-
eral recent studies were performed in different
countries to assess therapeutic value at market au-
thorization. In Germany, of 35 new chemical enti-
ties, 12 were considered novel substances, nine
were seen as an improvement, and 14 were “me
too” products [7]. In the Netherlands, of the 18
new drugs that came to market in 1999, only one
was classified as a possible important innovation;
the other 17 were considered no better than what
already existed [8]. In the United States, of 40 new
medicines entering the market in 1999, 19 were
classified as important contributions, many of
those in very small therapeutic areas or targeted to
small segments of the patient population [6]. In
Spain, of 42 new substances entering the market
in 1999, none was considered to be a major thera-
peutic breakthrough and only three were consid-
ered important improvements. All of those related
to the treatment of HIV/AIDS; those remaining
were considered no better than or only a minor
improvement over existing drugs [6]. Clearly, a
better definition of innovation and added thera-
peutic value is needed, and the various interpreta-
tions and judgments of what constitutes a real in-
novation need be worked out. This is an area that
policymakers and health industries will have to
examine more closely.
With regard to appropriate use of medicine,
more is to be gained from using medicines better
rather than examining specific intrinsic character-
istics of individual products. Although it has been
known for decades that significant unnecessary
and inappropriate prescribing takes place, that
drugs are used for the wrong indications, the
wrong dosage, and the wrong duration, irrational
drug use still occurs. There is tremendous poten-
tial for improvement. Reducing inappropriate and
unnecessary prescribing would free up money and
resources that could be used for needed innova-
tion and for more effective treatment. Govern-
ments have a role to play in this area just as they
have a role to play in promoting generic drug use.
 
The Future
 
In view of all the complex issues and the variety of
stakeholders and drivers in the pharmaceutical
sector and in health care as a whole, it is difficult
to foresee in which precise direction the pharma-
ceutical panorama will further develop. It will
greatly depend on the political choices that society
as a whole will make, and how much money it
will choose to make available for health. Science
and information technology will continue to have
hitherto unknown potential. To help think the
process through, in 1996 in the Netherlands a sce-
nario analysis was performed to examine how so-
ciety would develop and how health and health
care would be envisioned. Four scenarios were
outlined:
• Modesty in wealth: currently experienced in
wealthy nations. Public and private expendi-
ture are balanced and rational and cost-effec-
tive choices have to be made to optimize the
use of health resources.
• Risk avoidance: people do not wish to take
risks and they seem to have an aversion to
constantly being driven by technology and all
types of new products on the market. This sce-
nario includes rejecting new technology and
going back to nature.
• Driven by technology: whatever technology
developed by the industry is the driving force
in society.
• Free market in action: people assume that a
free market solves all problems; bad technology
is rejected by the market and good technology
finds its way through the health care system.
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Demographic and political forces in society will
determine future developments. The role of the
WHO Regional Office for Europe is to focus on
three aspects of pharmaceuticals, including distri-
bution of information, networking of countries,
and continued collaboration with individual mem-
ber states to improve their drug sector. This last
area particularly applies to the Eastern European
countries where WHO/EURO already has a sizable
number of programs assisting member states, min-
istries of health, and health insurance to develop
and implement viable pharmaceutical policies. In
the western part of the European region, WHO/
EURO has an international role and serves as a
platform for discussion, exchange, and dissemina-
tion of information regarding development of phar-
maceutical policies, particularly those concerning
pricing and reimbursement systems of drugs and
those concerning rational drug use. Better informa-
tion on drugs is needed, and we need to foster the
ability to assess various countries’ pharmaceutical
systems to apply lessons learned from past suc-
cesses and failures in pharmaceutical policymak-
ing. The WHO has taken this challenging direction
over the past year, promoting international collab-
oration and information exchange among coun-
tries and providing direct support to countries in
improving their pharmaceutical sector.
 
Question and Answer Period
 
Josephine Mauskopf, RTI Health Solutions, 
Research Triangle Park, NC
 
Do you have any specific ideas about how one
might encourage a pharmaceutical company to de-
velop a drug for tuberculosis or malaria?
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For the last one and a half years, under the leader-
ship of Dr Brundtland, our new director in Geneva
and former Prime Minister of Norway, discussion
has been taking place on this subject. Currently,
there is a bi-annual round table discussion involv-
ing the WHO, the pharmaceutical industry, Euro-
pean member states, and nongovernmental orga-
nizations and consumer groups, to examine these
issues. There is also increased interest from the
European Parliament and the European Union. It
is obviously a complex issue. Until now, the indus-
try was not interested in developing new drugs for
malaria. They were concerned that even if drugs
were available, there would be no one to pay for
them. It was concluded that we need enticements,
a sort of global trade-off for pharmaceutical prices,
or agreements could be reached between the indus-
try and governing bodies that include commitment
to research these underserved therapeutic areas. In
addition, international funds are being set up, such
as those at the World Bank and the Bill Gates Foun-
dation, to provide funding and guarantees that med-
icines developed by a pharmaceutical company will
be bought.
 
Stephen Chapman, Keele University, Keele, 
Staffordshire, UK
 
The main problem with the free market taking care
of the needs of populations is that it is very diffi-
cult to determine need in some developing coun-
tries and the former Soviet Union countries, princi-
pally due to the lack of good public health data
and the very small markets. As a state fragment
with a population of five million, the market in
Georgia becomes less competitive and less attrac-
tive to international pharmaceutical companies.
 
Unidentified Speaker #1
 
Does the WHO have any plans for collaborative
work with pharmaceutical companies to deal with
markets that are not commercially attractive?
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Scenario analysis is a science in itself, we must
consider the different options that society may fol-
low and map the possible routes. Based on avail-
able evidence, the free market scenario is clearly
not the best approach, particularly in transitional
countries, to achieve equitable access to essential
drugs. In many of the more affluent countries,
there is friction concerning the development of
health care systems and industrial interests. The
health care system of every country is a combina-
tion of those forces in society. WHO has ongoing
discussions with the industry, because we believe
that it should not be part of the problem but
rather part of the solution. Clearly, trying to un-
derstand all the different points of view, of con-
sumers, industry, and national government, is nec-
essary for a better understanding of the conflicts
and their solution.
 
François Schubert, Glaxo Wellcome R & D, 
Greenford, Middlesex, UK
 
Based on the experience we have from the Interna-
tional Conference on Harmonization (ICH), please
comment on international harmonization from a
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regulatory point of view. Do you foresee from the
members internationally or in Europe the same
movement for pharmacoeconomics requirements,
or not?
 
de Joncheere
 
WHO is an observer to the ICH process, and we
are close observers because of the implications it
has worldwide. From an official point of view, I do
not know whether or when there will be something
happening in the area of pharmacoeconomics. From
the scientific point of view, as the science of phar-
macoeconomics is evolving, there will be core issues
identified. Countries that will get increasingly in-
volved in those issues will start using those core ap-
proaches. Through scientific developments and ex-
change of information, some convergence should
take place among the different countries that are ex-
amining pharmacoeconomic data. From the point of
view of policy decisions, it is necessary to have the
data available regarding pharmacoeconomic evalua-
tions. From an overall public health perspective and
regarding affordability issues, available data to be
used may be different from one country to another.
In that respect, scientific development should take us
further.
 
John Parkinson, University of Dundee, Dundee, Scotland
 
You mentioned closing the gap between efficacy,
effectiveness, and outcomes and directive 75–318
says “normal conditions of use.” Could you com-
ment on the fact that phase three trials are clearly
necessary but many are not performed under nor-
mal conditions of use?
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A major issue here is the real gap between ap-
proved indications and what is happening when a
drug reaches the market in terms of clinical prac-
tice and real-world outcomes. There is a tremen-
dous scientific challenge there that needs to be
tackled, which should be facilitated and acceler-
ated by the information technology available now-
adays. It should also be possible to ensure that
information actually produced is being used in de-
cision making rather than considered interesting
but not applied.
 
This article was prepared with the assistance of BioMed-
Com Consultants inc.
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